TILT Biotherapeutics Overview
- Year Founded
-
2013

- Status
-
Private
- Employees
-
21

- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$2.28M
- Investors
-
10
TILT Biotherapeutics General Information
Description
Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment and eliminate its ability to suppress immune responses to cancer. The company's platform involves the utilization of oncolytic viruses for the enhancement of tumor cell therapy and will be used in tumor-infiltrating lymphocytes, chimeric antigen receptors, and checkpoints, enabling researchers to inhibit antibody therapy for solid tumors so as to achieve similar results.
Contact Information
- Tukholmankatu 8 B
- Biomedicum 2B, (2nd floor)
- 00290 Helsinki
- Finland
TILT Biotherapeutics Timeline
TILT Biotherapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
9. Accelerator/Incubator | 07-Feb-2023 | $2.28M | 000.00 | Completed | Clinical Trials - Phase 1 | |
8. Later Stage VC (Series A) | 07-Feb-2023 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
7. Later Stage VC | 16-Jun-2020 | 00.000 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
6. Equity Crowdfunding | 02-Apr-2020 | 00.000 | 0000 | 000.00 | Completed | Clinical Trials - Phase 1 |
5. Later Stage VC (Series A) | 04-Jun-2018 | Cancelled | Clinical Trials - Phase 1 | |||
4. Grant | 04-Jun-2018 | 00.000 | 00.00 | Completed | Clinical Trials - Phase 1 | |
3. Seed Round | 14-Dec-2016 | 00.000 | 00.00 | Completed | Pre-Clinical Trials | |
2. Seed Round | 30-Sep-2015 | $3.48M | $5.32M | 00.000 | Completed | Pre-Clinical Trials |
1. Seed Round | 01-Aug-2013 | $1.83M | $1.83M | 00.000 | Completed | Pre-Clinical Trials |
TILT Biotherapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 0,000,000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | ||
Ordinary | 0,000,000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | ||
Ordinary | 00,000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | ||
Series A | 212,713 | $16.94 | $16.94 | 1x | $16.94 | 1.15% | ||
Series A | 202,090 | $4.83 | $4.83 | 1x | $4.83 | 1.09% |
TILT Biotherapeutics Comparisons
Industry
Financing
Details
TILT Biotherapeutics Competitors (36)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Vyriad | Venture Capital-Backed | Rochester, MN | 00 | 00000 | 00000000000 | 00000 |
000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
00000 000000000000 | Formerly VC-backed | Waltham, MA | 000 | 00000 | 00000000 | 00000 |
000000000 00000000 | Venture Capital-Backed | Newark, CA | 0 | 000.00 | 00000000000 | 000.00 |
000000 000000000 | Angel-Backed | New York, NY | 00000 | 0000000000 | 00000 |
TILT Biotherapeutics Patents
TILT Biotherapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2023505925-A | Oncolytic viral vectors encoding variant interleukin-2 (vil-2) polypeptides | Pending | 11-Oct-2019 | 0000000000 | |
AU-2020361565-A1 | An oncolytic virus vector coding for variant interleukin-2 (vil-2) polypeptide | Pending | 11-Oct-2019 | 000000000 | |
CA-3157255-A1 | An oncolytic virus vector coding for variant interleukin-2 (vil-2) polypeptide | Pending | 11-Oct-2019 | 000000000 | |
EP-4041758-A1 | An oncolytic virus vector coding for variant interleukin-2 (vil-2) polypeptide | Pending | 11-Oct-2019 | 000000000 | |
AU-2020292610-A1 | Oncolytic adenovirus and checkpoint inhibitor combination therapy | Pending | 14-Jun-2019 | C12N15/86 |
TILT Biotherapeutics Executive Team (6)
TILT Biotherapeutics Board Members (8)
Name | Representing | Role | Since |
---|---|---|---|
Akseli Hemminki MD | TILT Biotherapeutics | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
Arto Linnervuo | Roschier | Legal Advisor & Board Member | 000 0000 |
Jyrki Liljeroos | Self | Deputy member of the board & Senior Business Advisor | 000 0000 |
Pekka Mattila | Self | Board Member | 000 0000 |
Timo Ahopelto | Lifeline Ventures | Strategy Adviser & Board Member | 000 0000 |
TILT Biotherapeutics Signals
TILT Biotherapeutics Investors (10)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
European Innovation Council Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
Tesi | Fund of Funds | Minority | 000 0000 | 000000 0 | |
Inrgrid Chen | Angel (individual) | Minority | 000 0000 | 000000 0 | |
PowerBank Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
European Commission | Government | Minority | 000 0000 | 000000 0 |